Obstructive Lung Diseases |

Reduction in Systemic Inflammation by the PDE4 Inhibitor Roflumilast in Patients With COPD FREE TO VIEW

Eduardo Marquez-martin, PhD; Francisco Ortega, PhD; Elena Campano; Carmen de la Horra, PhD; Jose Varela, PhD; Enrique Calderon, PhD
Author and Funding Information

Unidad Médico-Quirúrgica de Enfermedades Respiratorias. Hospital Universitario Virgen del Rocio, Seville, Spain

Chest. 2013;144(4_MeetingAbstracts):732A. doi:10.1378/chest.1703911
Text Size: A A A
Published online


SESSION TITLE: COPD Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD) that has anti-inflammatory properties in both airways and lung parenchyma. However, if roflumilast is able to reduce systemic inflammation in COPD patients remains speculative.

METHODS: In a post-marketing surveillance study, 21 men and one woman with severe COPD age 69.4 ± 7.7 years, received 500 mg roflumilast once daily for 12 weeks. Serum samples were collected before and after 12 weeks of treatment. Markers of inflammation were determined in serum samples using commercially available multiplex sandwich ELISA array (SearchLight, Billerica, MA, USA). Spirometry was performed at the start of roflumilast treatment and after 12 weeks.

RESULTS: Roflumilast significantly reduced the serum levels of proinflammatory cytokine interleukin (IL)-8 (16.6 ± 10 pg/ml vs 12.8 ± 9.5 pg/ml, p = 0.02). Levels of soluble IL-2 (5.3 ± 9.5 pg/ml vs 7.5 ± 10.2 pg/ml, p= 0.36), IL-4 (0.07 ±0.1 pg/ml vs 0.06 ± 0.1 pg/ml, p= 0.49)), IL-10 (1.3 ± 1.6 pg/ml vs 1.04 ± 1 pg/ml, p= 0.2) and IL-13 (1.2 ± 2.3pg/ml vs 1 ± 2.3 pg/mg, p= 0.67) were not affected by treatment. FEV1 remained stable during roflumilast treatment (831.14 cc ± 239.6 vs 873.55 cc ± 237.8, p= 0.11).

CONCLUSIONS: PDE4 inhibition by roflumilast treatment for 12 weeks reduced systemic inflammatory activity in patients with COPD.

CLINICAL IMPLICATIONS: Future studies are needed to further determine whether PDE4 inhibition can attenuate weight loss and muscle wasting related to systemic inflammation in COPD patients.

DISCLOSURE: The following authors have nothing to disclose: Eduardo Marquez-martin, Francisco Ortega, Elena Campano, Carmen de la Horra, Jose Varela, Enrique Calderon

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543